Rimegepant Suppliers & Bulk Manufacturers

Available Forms: Tablets

Available Strengths: 75 mg

Reference Brands: Nurtec ODT (USA), Vydura (EU)

Category: Neurology

Rimegepant is available in Tablets and strengths such as 75 mg. Sourced from GMP-certified and ISO-compliant manufacturers, this API meets global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical formulation and commercial manufacturing, Rimegepant is supplied in bulk quantities with complete regulatory support including DMF, COA, and MSDS.

Rimegepant can be exported to over 30 countries across Asia, Africa, Europe, and Latin America. Flexible packaging, competitive pricing, and a verified supplier network make Pharmatradz a trusted sourcing partner for pharmaceutical companies and contract manufacturers worldwide.

Product Description:

Rimegepant is a calcitonin gene-related peptide (CGRP) receptor antagonist used for both the acute treatment of migraine attacks with or without aura and the preventive treatment of episodic migraine in adults. Unlike conventional pain relievers, rimegepant is specifically designed to target the underlying mechanism of migraine rather than providing general pain relief. It is particularly beneficial for patients whose migraine symptoms are not adequately controlled with common analgesics such as acetaminophen, aspirin, or non-steroidal anti-inflammatory drugs.

Rimegepant is marketed under the brand name Nurtec ODT and is formulated as an orally disintegrating tablet, allowing it to dissolve on or under the tongue without the need for water. This convenient dosage form makes it suitable for use during migraine attacks, especially when nausea or vomiting is present. The drug works by selectively blocking CGRP receptors, which play a key role in migraine pathophysiology by mediating pain transmission and inflammation in the nervous system.

By inhibiting CGRP activity, rimegepant helps reduce migraine pain, associated symptoms, and attack frequency when used preventively. It does not cause vasoconstriction, making it an important therapeutic option for patients who may not tolerate or are contraindicated for triptan therapy.